Free Thinking: Behavioural economics
March 27, 2015 |
Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?
Books espousing behavioural economic theories, such as “Thinking Fast and Slow” authored by Daniel Kahneman, have become essential reading for market researchers looking to improve their understanding of how people think, feel and behave.
This theory can be very useful in consumer research, where we already know the power brands have on influencing purchase decisions. But can behavioural economics theory be applied to the pharmaceutical healthcare industry, where treatment decisions are often made in a highly regulated environment and by educated professionals using sound, rational judgement?
Download and read the complimentary whitepaper at http://bit.ly/1L5YhyM
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Preparing for ASH 2025: Pharma’s role in hematology innovation
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies…
AI without limits: A smarter, integrated approach to Medical Affairs
At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless…
What to expect from Obesity Week 2025: Key trends shaping the future of obesity care
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
AI with intent: How Inizio is redefining pharma through precision and partnership
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the…
Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight
Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.
Delivering purposeful solutions at Obesity Week 2025
We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.
Inizio strengthens executive team with new leadership appointments
Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™…
Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards
Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across…
Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care
Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.
Inizio appoints Ryan Quigley as CEO
Inizio have appointed Ryan Quigley as Chief Executive Officer, effective 9 September 2025. Paul Taaffe will remain closely involved with the company as an Advisor and board member going forward. …